Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R788 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | R788 50 mg PO bid |
| 2 | EXPERIMENTAL | R788 100 mg PO bid |
| 3 | EXPERIMENTAL | R788 150 mg PO bid |
| 4 | PLACEBO_COMPARATOR | Placebo PO bid |
| Name | Type | Description |
|---|---|---|
| R788 | DRUG | R788 50 mg, 100 mg, or 150 mg PO bid |
| Placebo | DRUG | Placebo PO bid |
Inclusion Criteria: 1. Patients must give written informed consent by signing an IRB-approved Informed Consent Form (ICF) prior to admission to this study. 2. Males and females, 18 to 75 years of age, with active RA for at least 12 months (functional class I-III, e.g., not bed or wheelchair-bound) ...
Top 20 of 28 competitors
R788 is an investigational small molecule being studied for the treatment of rheumatoid arthritis. It is in Phase 2 clinical development and has not been approved by the FDA. The drug is being evaluated in patients with this autoimmune condition to assess its safety and efficacy.
R788 targets Syk kinase, an enzyme involved in immune cell signaling. By inhibiting Syk kinase, R788 is designed to modulate the inflammatory response implicated in rheumatoid arthritis. This mechanism is the basis for its investigation as a potential treatment for the disease.
R788 is being developed by Rigel Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RIGL. The company is conducting clinical trials to evaluate the drug's potential in treating rheumatoid arthritis.
R788 is in Phase 2 clinical development for rheumatoid arthritis. It is an investigational drug, meaning it has not yet received regulatory approval. The Phase 2 trial has been completed, and the drug remains under evaluation for its safety and effectiveness.
R788 has been studied in a Phase 2 clinical trial with the identifier NCT00326339, titled 'Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)'. This completed trial enrolled 189 participants with rheumatoid arthritis and was conducted in the United States and Mexico.
Yes, R788 is also known as fostamatinib. It is an investigational small molecule Syk kinase inhibitor being developed by Rigel Pharmaceuticals for rheumatoid arthritis. The drug has completed a Phase 2 trial and remains in clinical development.